U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976944) titled 'Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer' on April 30.
Brief Summary: * Breast cancer is histologically divided into non-invasive (approximately 10%) and invasive (approximately 90%), with invasive cancer being the target of chemotherapy. Invasive carcinoma is classified into four subtypes according to the expression levels of hormone receptor (HR) and human epidermal growth factor receptor type 2 (HER2). Among them, triple negative breast cancer accounts for 10% of invasive cancers and is the subtype with the poorest prognosis.
* For triple negative breast cancer that is operable, chemotherapy wi...